8-K: Terns Pharmaceuticals Announces Positive Phase 1 Data for TERN-701, Highlighting Potential as Differentiated CML Treatment

Terns Pharmaceuticals reports promising Phase 1 pharmacokinetic data for TERN-701, showing it can be dosed without regard to food, a potential advantage over existing treatments for chronic myeloid leukemia (CML).

Summary

• Terns Pharmaceuticals announced positive interim results from a Phase 1 study of TERN-701, an allosteric BCR-ABL inhibitor, in healthy volunteers.
• The study evaluated the pharmacokinetics, food effect, safety, and tolerability of TERN-701.
• Results indicate that TERN-701 can be administered once daily with or without food, achieving clinically efficacious exposures.
• The pharmacokinetic profile of TERN-701 was linear with a median half-life ranging from 8 to 12 hours.
• At 80 mg and 160 mg doses, TERN-701 exposures met or exceeded predicted efficacious concentrations based on preclinical data.
• The food effect evaluation showed no clinically significant differences in plasma exposures when dosed with a high-fat meal compared to a fasted state.
• The ongoing Phase 1 CARDINAL trial is evaluating TERN-701 in CML patients, with interim data expected in the second half of 2024.
• The CARDINAL trial includes a dose escalation phase with doses ranging from 80mg to 500mg and a dose expansion phase.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and highlights a potential competitive advantage for TERN-701, suggesting a favorable outlook for the company's drug development program.

Positives

• TERN-701 demonstrates a favorable pharmacokinetic profile, supporting once-daily dosing.
• The lack of food effect with TERN-701 offers a significant convenience advantage over asciminib, which requires fasting.
• The drug achieved clinically efficacious exposures at tested doses.
• The safety and tolerability profile of TERN-701 in healthy volunteers was positive with no clinically meaningful changes observed.
• The results are consistent with previous studies in Chinese CML patients.

Risks

• The clinical development of TERN-701 is still ongoing, and further trials are needed to confirm its efficacy and safety in CML patients.
• The success of TERN-701 depends on the results of the CARDINAL trial and potential regulatory approvals.
• There are risks associated with the initiation, cost, timing, progress, results and utility of the company's research and development activities.
• The company's future financial condition is subject to uncertainties.

Future Outlook

Terns anticipates reporting interim dose escalation data from the ongoing Phase 1 CARDINAL trial in the second half of 2024 and plans to present the healthy volunteer data at an upcoming scientific conference.

Management Comments

• Emil Kuriakose, MD, chief medical officer at Terns Pharmaceuticals, stated that TERN-701 has the potential to be a differentiated BCR-ABL inhibitor with advantages over asciminib.
• Dr. Kuriakose also mentioned that the ability to dose with or without food is a key potential differentiator from asciminib.

Industry Context

The development of TERN-701 addresses the need for improved treatment options for CML patients who may not respond well to or tolerate existing active-site tyrosine kinase inhibitors. Allosteric BCR-ABL inhibitors represent a novel treatment class for CML and have the potential to address the shortcomings of active-site TKIs.

Comparison to Industry Standards

• The key comparator mentioned is asciminib, the only currently approved allosteric BCR-ABL inhibitor, which requires three hours of fasting with each dose and twice-daily dosing.
• TERN-701's ability to be dosed without regard to food is a significant advantage over asciminib.
• The document references Hansoh Pharmaceuticals' Phase 1 trial in China, indicating a global development effort for TERN-701.
• The document mentions that active-site TKIs have limitations due to resistance and intolerance, highlighting the need for new therapies like TERN-701.

Stakeholder Impact

• The positive results of the Phase 1 study are likely to be viewed favorably by shareholders.
• The potential for a more convenient treatment option could improve the quality of life for CML patients.
• The development of TERN-701 could lead to new opportunities for the company's employees and partners.

Next Steps

• The Phase 1 healthy volunteer study will proceed to enroll 320 mg and 400 mg dose cohorts.
• Terns plans to present the healthy volunteer data at an upcoming scientific conference.
• The company will continue the Phase 1 CARDINAL trial evaluating TERN-701 in CML patients, with interim data expected in the second half of 2024.

Key Dates

Keywords

TERN-701, BCR-ABL inhibitor, Chronic Myeloid Leukemia, CML, Pharmacokinetics, Clinical Trial, Oncology, Asciminib, Phase 1, Drug Development